PhageLife develops bacteriophage-based solutions for the targeted control of pathogenic bacteria in animal production, addressing the global challenge of antimicrobial resistance. The company integrates bioprospecting, genomic characterization, and advanced formulation to create strictly lytic phage cocktails against E. coli and Salmonella spp., preserving beneficial microbiota while reducing antibiotic dependence. Their platform emphasizes local strain adaptation and alignment with One Health and international export standards.
Funding
Funding not disclosed
Founders
Product
Problem
Livestock production faces structural challenges from regulatory restrictions on antimicrobial use, the rise of multidrug-resistant bacteria, and increasing international market demands for food safety and sustainability. Antimicrobial resistance threatens productivity, animal health, and sector competitiveness, while conventional antibiotics disrupt beneficial microbiota and contribute to the growing resistance crisis.
Solution
PhageLife provides a biotechnological platform based on strictly lytic bacteriophage cocktails for the specific control of pathogenic E. coli and Salmonella spp. in animal production. The company integrates directed bioprospecting, genomic safety characterization, and advanced cocktail engineering to deliver products that eliminate target pathogens without affecting beneficial microbiota. Their phages multiply in the presence of their target bacteria and naturally reduce in number as the bacterial population declines, enabling effective control at active infection sites. The technology is designed for compatibility with existing health management programs and aligned with One Health principles and international regulatory trends favoring antimicrobial reduction.
Target Audience
Primary customers are livestock producers and animal health companies seeking alternatives to conventional antibiotics, particularly in poultry and swine operations facing regulatory pressure to reduce antimicrobial use.
Features
- Strictly lytic phage cocktails engineered to broaden strain coverage and reduce the probability of bacterial resistance through multi-receptor targeting
- Genomic safety analysis of each phage candidate ensuring absence of antimicrobial resistance genes, virulence factors, and lysogenic potential
- Directed bioprospecting in local environments where pathogens and their natural phages coexist, enabling adaptation to regional conditions
- High biological specificity that preserves beneficial gut microbiota while eliminating only target pathogens
- Self-amplifying dynamic action where phages multiply in the presence of target bacteria and decline naturally as infection subsides
- Compatibility with existing animal health management programs, supporting integration into current production practices